Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 410

1.

Management of rare epithelial ovarian cancers.

Gershenson DM.

Clin Adv Hematol Oncol. 2019 Aug;17(8):444-446. No abstract available.

PMID:
31449512
2.

Management of Rare Ovarian Cancer Histologies.

Gershenson DM, Okamoto A, Ray-Coquard I.

J Clin Oncol. 2019 Sep 20;37(27):2406-2415. doi: 10.1200/JCO.18.02419. Epub 2019 Aug 12. No abstract available.

PMID:
31403866
3.

NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019.

Armstrong DK, Alvarez RD, Bakkum-Gamez JN, Barroilhet L, Behbakht K, Berchuck A, Berek JS, Chen LM, Cristea M, DeRosa M, ElNaggar AC, Gershenson DM, Gray HJ, Hakam A, Jain A, Johnston C, Leath CA III, Liu J, Mahdi H, Matei D, McHale M, McLean K, O'Malley DM, Penson RT, Percac-Lima S, Ratner E, Remmenga SW, Sabbatini P, Werner TL, Zsiros E, Burns JL, Engh AM.

J Natl Compr Canc Netw. 2019 Aug 1;17(8):896-909. doi: 10.6004/jnccn.2019.0039.

PMID:
31390583
4.

Correction: Focal Adhesion Kinase Targeting Using In vivo Short Interfering RNA Delivery in Neutral Liposomes for Ovarian Carcinoma Therapy.

Halder J, Kamat AA, Landen CN Jr, Han LY, Lutgendorf SK, Lin YG, Merritt WM, Jennings NB, Chavez-Reyes A, Coleman RL, Gershenson DM, Schmandt R, Cole SW, Lopez-Berestein G, Sood AK.

Clin Cancer Res. 2019 May 15;25(10):3194. doi: 10.1158/1078-0432.CCR-19-1132. No abstract available.

PMID:
31092618
5.

An international, phase III randomized trial in patients with mucinous epithelial ovarian cancer (mEOC/GOG 0241) with long-term follow-up: and experience of conducting a clinical trial in a rare gynecological tumor.

Gore M, Hackshaw A, Brady WE, Penson RT, Zaino R, McCluggage WG, Ganesan R, Wilkinson N, Perren T, Montes A, Summers J, Lord R, Dark G, Rustin G, Mackean M, Reed N, Kehoe S, Frumovitz M, Christensen H, Feeney A, Ledermann J, Gershenson DM.

Gynecol Oncol. 2019 Jun;153(3):541-548. doi: 10.1016/j.ygyno.2019.03.256. Epub 2019 Apr 18.

6.

Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference.

Bast RC Jr, Matulonis UA, Sood AK, Ahmed AA, Amobi AE, Balkwill FR, Wielgos-Bonvallet M, Bowtell DDL, Brenton JD, Brugge JS, Coleman RL, Draetta GF, Doberstein K, Drapkin RI, Eckert MA, Edwards RP, Elias KM, Ennis D, Futreal A, Gershenson DM, Greenberg RA, Huntsman DG, Ji JXY, Kohn EC, Iavarone C, Lengyel ER, Levine DA, Lord CJ, Lu Z, Mills GB, Modugno F, Nelson BH, Odunsi K, Pilsworth JA, Rottapel RK, Powell DJ Jr, Shen L, Shih IM, Spriggs DR, Walton J, Zhang K, Zhang R, Zou L.

Cancer. 2019 Jun 15;125(12):1963-1972. doi: 10.1002/cncr.32004. Epub 2019 Mar 5.

PMID:
30835824
7.

Mucinous borderline ovarian tumor versus invasive well-differentiated mucinous ovarian cancer: Difference in characteristics and outcomes.

Matsuo K, Machida H, Mandelbaum RS, Grubbs BH, Roman LD, Sood AK, Gershenson DM.

Gynecol Oncol. 2019 May;153(2):230-237. doi: 10.1016/j.ygyno.2019.02.003. Epub 2019 Feb 20.

PMID:
30797590
8.

Low grade serous ovarian carcinoma: identifying variations in practice patterns.

Siemon J, Gershenson DM, Slomovitz B, Schlumbrecht M.

Int J Gynecol Cancer. 2019 Jan;29(1):174-180. doi: 10.1136/ijgc-2018-000018.

PMID:
30640701
9.

Treatment of Rare Epithelial Ovarian Tumors.

Cobb LP, Gershenson DM.

Hematol Oncol Clin North Am. 2018 Dec;32(6):1011-1024. doi: 10.1016/j.hoc.2018.07.015. Review.

PMID:
30390757
10.

Complete Resection Is Essential in the Surgical Treatment of Gestational Trophoblastic Neoplasia.

Essel KG, Shafer A, Bruegl A, Gershenson DM, Drury LK, Ramondetta LM, Naumann RW, Brown J.

Int J Gynecol Cancer. 2018 Oct;28(8):1453-1460. doi: 10.1097/IGC.0000000000001348.

PMID:
30157165
11.

KMT2D/MLL2 inactivation is associated with recurrence in adult-type granulosa cell tumors of the ovary.

Hillman RT, Celestino J, Terranova C, Beird HC, Gumbs C, Little L, Nguyen T, Thornton R, Tippen S, Zhang J, Lu KH, Gershenson DM, Rai K, Broaddus RR, Futreal PA.

Nat Commun. 2018 Jun 27;9(1):2496. doi: 10.1038/s41467-018-04950-x.

12.

A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-254).

Chan JK, Brady W, Monk BJ, Brown J, Shahin MS, Rose PG, Kim JH, Secord AA, Walker JL, Gershenson DM.

Gynecol Oncol. 2018 Aug;150(2):247-252. doi: 10.1016/j.ygyno.2018.05.029. Epub 2018 Jun 18.

13.

Is carboplatin-based chemotherapy as effective as cisplatin-based chemotherapy in the treatment of advanced-stage dysgerminoma in children, adolescents and young adults?

Shah R, Xia C, Krailo M, Amatruda JF, Arul SG, Billmire DF, Brady WE, Covens A, Gershenson DM, Hale JP, Hurteau J, Murray MJ, Nicholson JC, Olson TA, Pashankar F, Rodriguez-Galindo C, Shaikh F, Stark D, Frazier AL, Stoneham S.

Gynecol Oncol. 2018 Aug;150(2):253-260. doi: 10.1016/j.ygyno.2018.05.025. Epub 2018 Jun 5.

14.

Phase II study of single-agent cabozantinib in patients with recurrent clear cell ovarian, primary peritoneal or fallopian tube cancer (NRG-GY001).

Konstantinopoulos PA, Brady WE, Farley J, Armstrong A, Uyar DS, Gershenson DM.

Gynecol Oncol. 2018 Jul;150(1):9-13. doi: 10.1016/j.ygyno.2018.04.572. Epub 2018 May 5.

15.

Clinical trial methodology in rare gynecologic tumor research: Strategies for success.

Brown J, Naumann RW, Brady WE, Coleman RL, Moore KN, Gershenson DM.

Gynecol Oncol. 2018 Jun;149(3):605-611. doi: 10.1016/j.ygyno.2018.04.008. Epub 2018 Apr 24. Review.

PMID:
29699802
16.

Accuracy of Intraoperative Frozen Section Diagnosis of Borderline Ovarian Tumors by Hospital Type.

Shah JS, Mackelvie M, Gershenson DM, Ramalingam P, Kott MM, Brown J, Gauthier P, Nugent E, Ramondetta LM, Frumovitz M.

J Minim Invasive Gynecol. 2019 Jan;26(1):87-93. doi: 10.1016/j.jmig.2018.04.005. Epub 2018 Apr 19.

PMID:
29680231
17.

Trends of low-grade serous ovarian carcinoma in the United States.

Matsuo K, Machida H, Grubbs BH, Sood AK, Gershenson DM.

J Gynecol Oncol. 2018 Jan;29(1):e15. doi: 10.3802/jgo.2018.29.e15. No abstract available.

18.

DICER1-related Sertoli-Leydig cell tumor and gynandroblastoma: Clinical and genetic findings from the International Ovarian and Testicular Stromal Tumor Registry.

Schultz KAP, Harris AK, Finch M, Dehner LP, Brown JB, Gershenson DM, Young RH, Field A, Yu W, Turner J, Cost NG, Schneider DT, Stewart DR, Frazier AL, Messinger Y, Hill DA.

Gynecol Oncol. 2017 Dec;147(3):521-527. doi: 10.1016/j.ygyno.2017.09.034. Epub 2017 Oct 14.

19.

FDA ovarian cancer clinical trial endpoints workshop: A Society of Gynecologic Oncology White Paper.

Herzog TJ, Ison G, Alvarez RD, Balasubramaniam S, Armstrong DK, Beaver JA, Ellis A, Tang S, Ford P, McKee A, Gershenson DM, Kim G, Monk BJ, Pazdur R, Coleman RL.

Gynecol Oncol. 2017 Oct;147(1):3-10. doi: 10.1016/j.ygyno.2017.08.012. Epub 2017 Aug 24. Review. No abstract available.

PMID:
28844539
20.

An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience.

Oliver KE, Brady WE, Birrer M, Gershenson DM, Fleming G, Copeland LJ, Tewari K, Argenta PA, Mannel RS, Secord AA, Stephan JM, Mutch DG, Stehman FB, Muggia FM, Rose PG, Armstrong DK, Bookman MA, Burger RA, Farley JH.

Gynecol Oncol. 2017 Nov;147(2):243-249. doi: 10.1016/j.ygyno.2017.08.004. Epub 2017 Aug 12.

21.

Impact of lympho-vascular space invasion on tumor characteristics and survival outcome of women with low-grade serous ovarian carcinoma.

Matsuo K, Wong KK, Fotopoulou C, Blake EA, Robertson SE, Pejovic T, Frimer M, Pardeshi V, Hu W, Choi JS, Sun CC, Richmond AM, Marcus JZ, Hilliard MAM, Mostofizadeh S, Mhawech-Fauceglia P, Abdulfatah E, Post MD, Saglam O, Shahzad MMK, Karabakhtsian RG, Ali-Fehmi R, Gabra H, Roman LD, Sood AK, Gershenson DM.

J Surg Oncol. 2018 Feb;117(2):236-244. doi: 10.1002/jso.24801. Epub 2017 Aug 8.

22.

Salvage chemotherapy for gestational trophoblastic neoplasia: Utility or futility?

Essel KG, Bruegl A, Gershenson DM, Ramondetta LM, Naumann RW, Brown J.

Gynecol Oncol. 2017 Jul;146(1):74-80. doi: 10.1016/j.ygyno.2017.04.017. Epub 2017 May 2.

PMID:
28473205
23.

Hormonal Maintenance Therapy for Women With Low-Grade Serous Cancer of the Ovary or Peritoneum.

Gershenson DM, Bodurka DC, Coleman RL, Lu KH, Malpica A, Sun CC.

J Clin Oncol. 2017 Apr 1;35(10):1103-1111. doi: 10.1200/JCO.2016.71.0632. Epub 2017 Feb 21.

24.

ELF3 is a negative regulator of epithelial-mesenchymal transition in ovarian cancer cells.

Yeung TL, Leung CS, Wong KK, Gutierrez-Hartmann A, Kwong J, Gershenson DM, Mok SC.

Oncotarget. 2017 Mar 7;8(10):16951-16963. doi: 10.18632/oncotarget.15208.

25.

Activity of bevacizumab-containing regimens in recurrent low-grade serous ovarian or peritoneal cancer: A single institution experience.

Dalton HJ, Fleming ND, Sun CC, Bhosale P, Schmeler KM, Gershenson DM.

Gynecol Oncol. 2017 Apr;145(1):37-40. doi: 10.1016/j.ygyno.2017.01.027. Epub 2017 Jan 27.

26.

Role of hysterectomy and lymphadenectomy in the management of early-stage borderline ovarian tumors.

Matsuo K, Machida H, Takiuchi T, Grubbs BH, Roman LD, Sood AK, Gershenson DM.

Gynecol Oncol. 2017 Mar;144(3):496-502. doi: 10.1016/j.ygyno.2017.01.019. Epub 2017 Jan 26.

PMID:
28131526
27.

Ovarian Sex Cord-Stromal Tumors.

Schultz KA, Harris AK, Schneider DT, Young RH, Brown J, Gershenson DM, Dehner LP, Hill DA, Messinger YH, Frazier AL.

J Oncol Pract. 2016 Oct;12(10):940-946.

28.

Management of borderline ovarian tumours.

Gershenson DM.

Best Pract Res Clin Obstet Gynaecol. 2017 May;41:49-59. doi: 10.1016/j.bpobgyn.2016.09.012. Epub 2016 Oct 3. Review.

PMID:
27780698
29.

Conundrums in the management of malignant ovarian germ cell tumors: Toward lessening acute morbidity and late effects of treatment.

Gershenson DM, Frazier AL.

Gynecol Oncol. 2016 Nov;143(2):428-432. doi: 10.1016/j.ygyno.2016.08.329. Epub 2016 Aug 25. Review.

PMID:
27569583
30.

Ovarian Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology.

Morgan RJ Jr, Armstrong DK, Alvarez RD, Bakkum-Gamez JN, Behbakht K, Chen LM, Copeland L, Crispens MA, DeRosa M, Dorigo O, Gershenson DM, Gray HJ, Hakam A, Havrilesky LJ, Johnston C, Lele S, Martin L, Matulonis UA, O'Malley DM, Penson RT, Percac-Lima S, Pineda M, Plaxe SC, Powell MA, Ratner E, Remmenga SW, Rose PG, Sabbatini P, Santoso JT, Werner TL, Burns J, Hughes M.

J Natl Compr Canc Netw. 2016 Sep;14(9):1134-63.

PMID:
27587625
31.

Loss of ARID1A expression leads to sensitivity to ROS-inducing agent elesclomol in gynecologic cancer cells.

Kwan SY, Cheng X, Tsang YT, Choi JS, Kwan SY, Izaguirre DI, Kwan HS, Gershenson DM, Wong KK.

Oncotarget. 2016 Aug 30;7(35):56933-56943. doi: 10.18632/oncotarget.10921.

32.

Low-grade serous carcinoma of the ovary or peritoneum.

Gershenson DM.

Ann Oncol. 2016 Apr;27 Suppl 1:i45-i49. doi: 10.1093/annonc/mdw085. Review.

PMID:
27141071
33.

Small cell carcinoma of the ovary-hypercalcemic type (SCCOHT): A review of 47 cases.

Callegaro-Filho D, Gershenson DM, Nick AM, Munsell MF, Ramirez PT, Eifel PJ, Euscher ED, Marques RM, Nicolau SM, Schmeler KM.

Gynecol Oncol. 2016 Jan;140(1):53-7. doi: 10.1016/j.ygyno.2015.11.004. Epub 2015 Nov 4.

34.

Is adjuvant chemotherapy indicated in ovarian immature teratomas? A combined data analysis from the Malignant Germ Cell Tumor International Collaborative.

Pashankar F, Hale JP, Dang H, Krailo M, Brady WE, Rodriguez-Galindo C, Nicholson JC, Murray MJ, Bilmire DF, Stoneham S, Arul GS, Olson TA, Stark D, Shaikh F, Amatruda JF, Covens A, Gershenson DM, Frazier AL.

Cancer. 2016 Jan 15;122(2):230-7. doi: 10.1002/cncr.29732. Epub 2015 Oct 20. Erratum in: Cancer. 2018 Mar 15;124(6):1302.

35.

Impact of mutational status on survival in low-grade serous carcinoma of the ovary or peritoneum.

Gershenson DM, Sun CC, Wong KK.

Br J Cancer. 2015 Nov 3;113(9):1254-8. doi: 10.1038/bjc.2015.364. Epub 2015 Oct 20.

36.

Characteristics of ovarian tumors of low malignant potential in BRCA mutation carriers: A case series.

Matsuo K, Tierney KE, Schneider DM, Mhawech-Fauceglia P, Roman LD, Gershenson DM.

Gynecol Oncol Rep. 2015 Jun 11;13:36-9. doi: 10.1016/j.gore.2015.06.003. eCollection 2015 Aug.

37.

Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian Cancer.

Grisham RN, Sylvester BE, Won H, McDermott G, DeLair D, Ramirez R, Yao Z, Shen R, Dao F, Bogomolniy F, Makker V, Sala E, Soumerai TE, Hyman DM, Socci ND, Viale A, Gershenson DM, Farley J, Levine DA, Rosen N, Berger MF, Spriggs DR, Aghajanian CA, Solit DB, Iyer G.

J Clin Oncol. 2015 Dec 1;33(34):4099-105. doi: 10.1200/JCO.2015.62.4726. Epub 2015 Aug 31.

38.

Pediatric and Adolescent Extracranial Germ Cell Tumors: The Road to Collaboration.

Olson TA, Murray MJ, Rodriguez-Galindo C, Nicholson JC, Billmire DF, Krailo MD, Dang HM, Amatruda JF, Thornton CM, Arul GS, Stoneham SJ, Pashankar F, Stark D, Shaikh F, Gershenson DM, Covens A, Hurteau J, Stenning SP, Feldman DR, Grimison PS, Huddart RA, Sweeney C, Powles T, Lopes LF, dos Santos Agular S, Chinnaswamy G, Khaleel S, Abouelnaga S, Hale JP, Frazier AL.

J Clin Oncol. 2015 Sep 20;33(27):3018-28. doi: 10.1200/JCO.2014.60.5337. Epub 2015 Aug 24. Review. Erratum in: J Clin Oncol. 2015 Nov 20;33(33):3981.

39.

Nutlin-3a: A Potential Therapeutic Opportunity for TP53 Wild-Type Ovarian Carcinomas.

Crane EK, Kwan SY, Izaguirre DI, Tsang YT, Mullany LK, Zu Z, Richards JS, Gershenson DM, Wong KK.

PLoS One. 2015 Aug 6;10(8):e0135101. doi: 10.1371/journal.pone.0135101. eCollection 2015.

40.

Impact of Age and Primary Disease Site on Outcome in Women With Low-Grade Serous Carcinoma of the Ovary or Peritoneum: Results of a Large Single-Institution Registry of a Rare Tumor.

Gershenson DM, Bodurka DC, Lu KH, Nathan LC, Milojevic L, Wong KK, Malpica A, Sun CC.

J Clin Oncol. 2015 Aug 20;33(24):2675-82. doi: 10.1200/JCO.2015.61.0873. Epub 2015 Jul 20.

41.

Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma.

Slomovitz BM, Jiang Y, Yates MS, Soliman PT, Johnston T, Nowakowski M, Levenback C, Zhang Q, Ring K, Munsell MF, Gershenson DM, Lu KH, Coleman RL.

J Clin Oncol. 2015 Mar 10;33(8):930-6. doi: 10.1200/JCO.2014.58.3401. Epub 2015 Jan 26.

42.

Intratumoral heterogeneity in a minority of ovarian low-grade serous carcinomas.

Tone AA, McConechy MK, Yang W, Ding J, Yip S, Kong E, Wong KK, Gershenson DM, Mackay H, Shah S, Gilks B, Tinker AV, Clarke B, McAlpine JN, Huntsman D.

BMC Cancer. 2014 Dec 18;14:982. doi: 10.1186/1471-2407-14-982.

43.

Updates and emerging therapies for rare epithelial ovarian cancers: one size no longer fits all.

Groen RS, Gershenson DM, Fader AN.

Gynecol Oncol. 2015 Feb;136(2):373-83. doi: 10.1016/j.ygyno.2014.11.078. Epub 2014 Dec 3. Review.

PMID:
25481800
44.

The role of secondary cytoreduction in low-grade serous ovarian cancer or peritoneal cancer.

Crane EK, Sun CC, Ramirez PT, Schmeler KM, Malpica A, Gershenson DM.

Gynecol Oncol. 2015 Jan;136(1):25-9. doi: 10.1016/j.ygyno.2014.11.005. Epub 2014 Nov 8.

45.

Summary of the 2014 MD Anderson International Meeting in Gynecologic Oncology: emerging therapies in gynecologic cancer.

Abu-Rustum N, Chi D, Coleman RL, del Campo JM, Fotopoulou C, Frumovitz M, Gershenson DM, Gonzalez A, Jhingran A, Ledermann J, Mariani A, Mirza M, Oaknin A, Ramirez PT, Schmeler KM, Sood AK.

Gynecol Oncol. 2014 Jul;134(1):6-9. doi: 10.1016/j.ygyno.2014.04.042. No abstract available.

PMID:
24952408
46.

Prognostic factors in malignant ovarian germ cell tumours (The Surveillance, Epidemiology and End Results experience 1978-2010).

Solheim O, Gershenson DM, Tropé CG, Rokkones E, Sun CC, Weedon-Fekjaer H, FossÄ SD.

Eur J Cancer. 2014 Jul;50(11):1942-50. doi: 10.1016/j.ejca.2014.03.288. Epub 2014 May 20.

PMID:
24857045
47.

KRAS (but not BRAF) mutations in ovarian serous borderline tumour are associated with recurrent low-grade serous carcinoma.

Tsang YT, Deavers MT, Sun CC, Kwan SY, Kuo E, Malpica A, Mok SC, Gershenson DM, Wong KK.

J Pathol. 2013 Dec;231(4):449-56. doi: 10.1002/path.4252.

48.

Utility of 18F-FDG PET/CT in follow-up of patients with low-grade serous carcinoma of the ovary.

Takeuchi S, Lucchini M, Schmeler KM, Coleman RL, Gershenson DM, Munsell MF, Macapinlac HA, Ramirez PT.

Gynecol Oncol. 2014 Apr;133(1):100-4. doi: 10.1016/j.ygyno.2014.02.008. Epub 2014 Feb 15.

49.

The prognostic significance of pre- and post-treatment CA-125 in grade 1 serous ovarian carcinoma: a gynecologic Oncology Group study.

Fader AN, Java J, Krivak TC, Bristow RE, Tergas AI, Bookman MA, Armstrong DK, Tanner EJ, Gershenson DM.

Gynecol Oncol. 2014 Mar;132(3):560-5. doi: 10.1016/j.ygyno.2013.11.016. Epub 2013 Dec 13.

50.

Efficacy and safety of bevacizumab in recurrent sex cord-stromal ovarian tumors: results of a phase 2 trial of the Gynecologic Oncology Group.

Brown J, Brady WE, Schink J, Van Le L, Leitao M, Yamada SD, de Geest K, Gershenson DM.

Cancer. 2014 Feb 1;120(3):344-51. doi: 10.1002/cncr.28421. Epub 2013 Oct 24.

Supplemental Content

Loading ...
Support Center